Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ApollomicsAPLM -0.56%30 Equity-to-Asset is -0.48 as of Dec. 2025. GuruFocus rates APLM with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 1,416 Biotechnology companies, Apollomics ranks worse than 90.96% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Apollomics's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-3.19 Mil. Apollomics's Total Assets for the quarter that ended in Dec. 2025 was $6.71 Mil.
The historical rank and industry rank for Apollomics's Equity-to-Asset or its related term are showing as below:
APLM'
s Equity-to-Asset Range Over the Past 10 Years
Min: -5.86 Med: -0.61 Max: 0.74
Current: -0.48
During the past 6 years, the highest Equity to Asset Ratio of Apollomics was 0.74. The lowest was -5.86. And the median was -0.61.
APLM's Equity-to-Asset is ranked worse than 90.96% of 1416
companies
in the Biotechnology industry
Industry Median: 0.68
vs APLM: -0.48
Apollomics (NAS:APLM) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Apollomics Equity-to-Asset Related Terms
Apollomics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Apollomics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APLM vs HYPD, MGX, KALA: Equity-to-Asset Comparison
For the Biotechnology subindustry, Apollomics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apollomics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apollomics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Apollomics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Apollomics's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apollomics (APLM) has a Equity-to-Asset of -0.48 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Apollomics and its competitors. According to the industry distribution chart, Apollomics ranks #1288 out of 1416 companies in the Biotechnology industry, placing it in the top 91%.
Is Apollomics' Equity-to-Asset too high?
Apollomics' current Equity-to-Asset is -0.48. Based on the distribution chart, Apollomics ranks #1288 out of 1416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Apollomics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' Equity-to-Asset compare to HYPD and MGX?
According to the Biotechnology industry distribution chart, Apollomics ranks #1288 out of 1416 companies for Equity-to-Asset. This places Apollomics in the lower half of its industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,416 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Apollomics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apollomics's current Equity-to-Asset is -0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLM) has a current Equity-to-Asset of -0.48. The current Equity-to-Asset is -0.48. Apollomics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Apollomics (APLM), the current Equity-to-Asset is -0.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
30GF Score
Get the complete analysis for APLM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APLM has been successfully added to your 
